Ubs Group Ag Apellis Pharmaceuticals, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding APLS
# of Institutions
310Shares Held
113MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$466 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$356 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$333 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$174 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.29B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...